TLR9
ENSG00000239732
Target class
Membrane receptor
Chromosome
3
Approved drugs
1
Clinical candidates (approved and in development)
9
- Approved drugs
- 1
- Clinical candidates (approved and in development)
- 9
- Chemical probe available
- Yes
- Other names
- CD289
- Target name
- TLR9
- Gene name
- Toll like receptor 9
- Gene symbol
- TLR9
- Protein name
- Toll-like receptor 9 (CD antigen CD289)
- Gene biotype
- Protein coding
- Gene family
- CD molecules|Toll like receptors|My-T-BRC complex
- Target class
- Membrane receptor
- Target type
- Human gene
- Tissues expressed in
- 29
- Highest tissue expression
- 13.1
- Tissue specificity (Gini)
- 0.515
- Tissue specificity (tau)
- 0.877
- KEGG gene identifiers
- hsa:54106
- Protein interaction confidence
- 0.827167
- Protein interaction partners
- 78
- R-HSA-109704
- R-HSA-1679131
- R-HSA-168138
- R-HSA-9679191
- R-HSA-975110
- R-HSA-975138
- R-HSA-975155
- End position
- 52225645
- Start position
- 52221080
- Chromosome
- 3
- Strand
- Reverse
- Endoplasmic reticulum membrane
- Single-pass type I membrane protein . Early endosome membrane . Lysosome . Cytoplasmic vesicle, phagosome . Golgi apparatus membrane . Note=Relocalizes from endoplasmic reticulum to endosome and lysosome upon stimulation with agonist. Exit from the ER requires UNC93B1. Endolysosomal localization is required for proteolytic cleavage and subsequent activation. Intracellular localization of the active receptor may prevent from responding to self nucleic acid. .
- PubMed 14716310
- PubMed 38169466
- Tissue specificity (tau)
- 0.877128
- Expression inequality (Gini)
- 0.514708
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes
- 13.1
- Spleen
- 8.33
- Whole Blood
- 6.3
- Brain - Cerebellum
- 5.96
- Brain - Cerebellar Hemisphere
- 5.24
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes13.1
- Spleen8.33
- Whole Blood6.3
- Brain - Cerebellum5.96
- Brain - Cerebellar Hemisphere5.24
- Cervix - Endocervix3.61
- Ovary3.34
- Small Intestine - Terminal Ileum3.08
- Cervix - Ectocervix2.66
- Fallopian Tube2.47
- Uterus2.37
- Nerve - Tibial2.19
- Artery - Aorta2.17
- Bladder1.98
- Vagina1.8
- Colon - Sigmoid1.78
- Esophagus - Gastroesophageal Junction1.71
- Prostate1.63
- Artery - Tibial1.6
- Artery - Coronary1.5
- Esophagus - Muscularis1.49
- Thyroid1.49
- Lung1.47
- Colon - Transverse1.32
- Testis1.29
And 29 more, listed on the interactive page.
- GO:0002224
- GO:0002639
- GO:0010628
- GO:0030890
- GO:0032490
- GO:0032722
- GO:0032725
- GO:0032727
- GO:0032728
- GO:0032729
- GO:0032755
- GO:0032757
- GO:0034162
- GO:0043123
- GO:0043410
- GO:0045087
- GO:0045577
- GO:0046330
- GO:0050729
- GO:0050829
- GO:0050871
- GO:1901895
- GO:0000139
- GO:0005737
- GO:0005783
- GO:0005789
- GO:0005886
- GO:0010008
- GO:0016323
- GO:0016324
- GO:0031901
- GO:0036020
- GO:0005149
- GO:0035197
- GO:0038187
Related records
Trials (502)
- #StayHome: Early Hydroxychloroquine to Reduce Secondary Hospitalisation and Household Transmission in COVID-19
- A Comparative Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in Bangladesh
- A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19
- A Dose Finding Study of CpG in Patients With Chronic Lymphocytic Leukemia Who Have Been Previously Treated
- A Multicentre, Randomised, Double-blind, Positive-control Clinical Trial Evaluating Dihydroartemisinin Tablets for the Treatment of Discoid Lupus Erythematosus
- A Phase 2 Intratumoral Injection PF-3512676 Plus Local Radiation in Low-Grade B-Cell Lymphomas
- A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic Melanoma
- A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma
- A Phase II Trial of Combined Hydroxychloroquine and Sirolimus in Soft Tissue Sarcoma
- A Pilot Study of NY-ESO-1b Peptide Plus CpG 7909 and Montanide® ISA-51 in Patients With Cancer.
- A Preventive Treatment for Migrant Workers at High-risk of COVID-19
- A Randomised Trial Investigating the Additional Benefit of Hydroxychloroquine(HCQ)to Short Course Radiotherapy (SCRT) in Patients Aged 70 Years and Older With High Grade Gliomas (HGG)
- A Randomized Controlled Clinical Trial: Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients
- A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 Melanoma
- a Retrospective Study on the Systemic Treatment of LPP and FFA
- A Safety and Efficacy Study of a Single or Double Dose of HEPLISAV™ Hepatitis B Vaccine in Adults With End-Stage Renal Disease
- A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes
- A Study of 1018 Immunostimulatory Sequence (ISS) Administered With Irinotecan and Cetuximab to Treat Patients With Previously Treated Metastatic Colorectal Cancer
- A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma
- A Study of Combination Therapies to Treat COVID-19 Infection
Drugs (11)
- 1018 ISS Toll-like receptor 9 agonist
- Agatolimod Toll-like receptor 9 agonist
- Agatolimod sodium Toll-like receptor 9 agonist
- Bazlitoran Toll-like receptor 9 antagonist
- Cobitolimod Toll-like receptor 9 agonist
- EMD-1201081 Toll-like receptor 9 agonist
- Hydroxychloroquine Toll-like receptor 9 antagonist
- Hydroxychloroquine sulfate Toll-like receptor 9 antagonist
- Lefitolimod Toll-like receptor 9 agonist
- Tilsotolimod Toll-like receptor 9 agonist
- Tilsotolimod sodium Toll-like receptor 9 agonist